Immunotherapy-induced coeliac disease in curative lung cancer

Hannah Walton, Samantha Hopkins, Alan Shand, Shahida Din

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The advent of immunotherapy has revolutionised the treatment of metastatic lung cancer and it has recently been established as the standard of care in the radical treatment of lung cancer. However, immune-related adverse events (IrAEs) frequently occur in patients treated with immunotherapy, and rare IrAEs continue to be identified. We report a case of immunotherapy-induced coeliac disease due to adjuvant durvalumab post-chemoradiotherapy in a patient receiving curative treatment for lung cancer. The patient had raised anti-tissue transglutaminase IgA and histological findings consistent with coeliac disease. This is the first published case report of probable immunotherapy-induced coeliac disease both with the immunotherapy drug durvalumab and in the curative lung cancer setting.
Original languageEnglish
Pages (from-to)e243406
JournalBMJ Case Reports
Issue number9
Early online date27 Sept 2021
Publication statusE-pub ahead of print - 27 Sept 2021


Dive into the research topics of 'Immunotherapy-induced coeliac disease in curative lung cancer'. Together they form a unique fingerprint.

Cite this